Mlp Saglik Hizmetleri As Class B · BIST:MPARK

Mlp Saglik Hizmetleri As Class B — MLP Care — 9M 2021 Earnings Presentation

25 slides from Mlp Saglik Hizmetleri As Class B's earnings presentation, Nov 5, 2021

  1. Slide 1: MLP Care 9M 2021 Presentation

    MLP CARE 9M 2021 PRESENTATION NOVEMBER 5, 2021

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation may contain certain forward-looking statements concerning MLP Care’s future performance and should be considered as good faith estimates made by the Company. These forward-looking statements reflect management expectations and are based upon currently ava

  3. Slide 3: Muharrem Usta, Chairman & CEO

    MUHARREM USTA CHAIRMAN & CEO MLPCARE MEDICALPARK | Lit/nosprtaL

  4. Slide 4: Snapshot of Pandemic in Turkey and Vaccination

    Snapshot of Pandemic in Turkey as of November 4, 2021 Population : 84.3 m Snapshot of Pandemic in Turkey as of 01.03.2021 Total Cases 8.2 m Daily Cases (Weekly 27.0 k Average) Total: 117.0 m Total 71.5 k Total Number of Deaths Vaccination 1st Dose: 55.5 m 0.9% Fatality 65.9% of the population 2nd Do

  5. Slide 5: At a Glance: MLP Care Q3 2021 Financial Highlights

    At a Glance: MLP Care Q3 2021 Financial Highlights (w/o fx impact)  Continued robust uptick in domestic Adj. EBITDA Revenue patient revenues quarter-on-quarter and the accelerated recovery of foreign TL 1,498 m TL 396 m medical tourism revenues 39% Growth 42% Growth 9M 2021: 9M 2021: 44% Growth 48%

  6. Slide 6: # of People with Top-up Insurance Close to 2.2 million

    # of People with Top-up Insurance Close to 2.2 million # of People with Insurance in Turkey (in thousand) 2,453 2,192 4,645 2,332 1,640 3,972 Growth (9M 2020 – 9M 2021) 5.2% 33.6% 16.9% PMI Top-up PMI+Top-up # of People with Top-up Insurance in Turkey (in thousand) 09.2021; 2,192 2,000 09.2020; 1,64

  7. Slide 7: Significant Growth Potential of FMT Revenue

    Significant Growth Potential of FMT Revenue Medical Tourism Revenue (USD m) TOP 10 FMT Revenue % by Department in 9M 2021 12.2% (36.7%) 68.6% 32.7% (42.3%) 37.4% 77 11% 10% 9% 68 7% 6% 59 57 5% 4% 52 49 3% 3% 2% 37 34 General Surgery Cardiology Hematology Orthopedics Hematology Diseases Oncology Bra

  8. Slide 8: At a Glance: MLP Care Operational Highlights

    At a Glance: MLP Care Operational Highlights Two brands and one concept targeting three different price points with The largest hospital group in 30 Hospitals in consistently outstanding medical service Total Turkey quality Established in 1993, listed on BIST in 2018 ~18,000 Staff 1 ~6,000 Beds in T

  9. Slide 9: Liv Hospital VadIstanbul Hospital Ramps Up

    Liv Hospital VadIstanbul Hospital Ramps Up Map of Istanbul Liv Hospital VadIstanbul Hospitals with Medical Park Brand Location: Sarıyer / Istanbul Hospitals with Liv Hospital Brand Opening Date: May 2021 Key Statistics  37k sqm  125 bed capacity  76 policlinic rooms  7 operating rooms  MLP Care

  10. Slide 10: Burcu Öztürk, CFO

    BURCU OZTURK CFO MLPCARE MEDICALPARK | Lit/nosprtaL

  11. Slide 11: Strong Revenue Growth

    Strong Revenue Growth Revenue (TLm) 43.6% 4,040 39.3% 2,814 1,498 1,075 Q3 2020 Q3 2021 9M 2020 9M 2021 Denotes growth of Revenue vs. the same period of the last year 11

  12. Slide 12: Double Digit Growth in Multiple Revenue Segments

    Double Digit Growth in Multiple Revenue Segments 9M 2021 (36%) 103%  Revenue from SSI was up by 23% in Q3 2021 3% (SSI Insurance allows for a wide addressable market, which is c.98% of the total population) 11% 27% 25%  Self pay was up by 21% in Q3 2021  Revenue from PMI, Top-up & Contracted Inst

  13. Slide 13: Strong Domestic and FMT Revenue Growth Continued

    Strong Domestic and FMT Revenue Growth Continued Domestic Patient Revenue Medical Tourism Ancillary Business Revenue 44.4% 103.1% (36.5%) 34.6% 126.8% 3,457 (14.6%) 460 122 207 58 1,232 Q3 2021 9M 2021 Q3 2021 9M 2021 Q3 2021 9M 2021 Domestic Revenue q-o-q Growth Accelerated Growth of Foreign Decrea

  14. Slide 14: Continued Improvement in Average Prices

    Continued Improvement in Average Prices Outpatient Revenues (TLm) Inpatient Revenues (TLm) 53.0% 38.9% 37.8% 28.5% 15.2% 10.5% 352 416 141 1,424 153 2,033 931 1,464 9M 2020 Volume & Mix Price 9M 2021 9M 2020 Volume & Mix Price 9M 2021 Average Revenue Per Visit (ARPV) Average Revenue Per Protocol (AR

  15. Slide 15: EBITDA Growth on the Back of Strong Revenue Recovery

    EBITDA Growth on the Back of Strong Revenue Recovery EBITDA1 (TLm) EBITDA2 (TLm) (w/o fx impact) 39.5% 48.5% 1,068 1,029 766 42.2% 26.0% 693 392 396 312 279 Q3 2020 1 Q3 2021 1 9M 2020 1 9M 2021 1 Q3 2020 2 Q3 2021 2 9M 20202 9M 2021 2 1 Adj. EBITDA: EBITDA TFRS adjustments that have no cash impact

  16. Slide 16: Prudent Cost Management

    Prudent Cost Management Cost of Service and G&A Expenses as a % of Revenues Cost Saving Measures enables us to reach the favourable EBITDA Margin Adj. EBITDA Margin 27.2% 26.4%  Material costs as a % of revenue declined in 9M 2021 0.9% 0.9% due to decrease in the share of laboratory business which

  17. Slide 17: Strong Net Profit Improvement

    Strong Net Profit Improvement Net Profit (TLm) Net Profit (TLm) Allocated to Equity Holders of the Parent 315.3% 610.3% 215 165 224.4% 13 41 52 (4) 18 23 Q3 2020 Q3 2021 9M 2020 9M 2021 Q3 2020 Q3 2021 9M 2020 9M 2021 Denotes growth of Net Profit and Net Profit Allocated to Equity Holders of the Par

  18. Slide 18: Net Debt Decreased

    Net Debt Decreased FX BASED NET DEBT 1 (in EUR m) GROSS DEBT PERCENTAGE 2020 9M 2021 EUR30m EUR32m EUR23m equivalent of equivalent of equivalent of Cash Balance 676mTL Cash Balance 375mTL FX Cash FX Cash FX Cash Balance Balance Balance 15% 26% 74% 85% 65 51 Net Debt 2,117mTL Net Debt 1,967mTL (3) No

  19. Slide 19: Improved Free Cash Flow and Operating Cash Flow

    Improved Free Cash Flow and Operating Cash Flow Maintenance Capex (TLm) Total Capex (TLm) OCF/ EBITDA FCF/ EBITDA 102.6% 79.7% 2.6% 6.1% 89.8% 75.7% 1,096 851 2.0% 245 104 3.9% 688 580 56 108 9M 2020 9M 2021 9M 2020 9M 2021 9M 2020 9M 2021 9M 2020 9M 2021 % of Revenue % of Revenue % of EBITDA % of E

  20. Slide 20: Q&A

    Q&A MLPCARE MEDICALPARK | Lit/nosprtaL

  21. Slide 21: Closing Remarks

    Closing Remarks MUHARREM USTA CHAIRMAN & CEO

  22. Slide 22: Thank You!

    Thank You! MLP Care Investor Relations Deniz Can Yücel +90 212 227 5555 (Ext: 1148) deniz.yucel@mlpcare.com http://investor.mlpcare.com/en/

  23. Slide 23: Historical Balance Sheet

    Historical Balance Sheet Unaudited Unaudited Audited TLm September 30, 2021 September 30, 2020 December 31, 2020 Cash and cash equivalents 676 492 375 Trade receivables 1,359 1,115 1,155 Inventory 122 112 113 Short term other assets 537 479 542 Current assets 2,694 2,198 2,185 Tangible and intangibl

  24. Slide 24: Historical P&L Statements

    Historical P&L Statements Unaudited Unaudited Unaudited Unaudited TLm 9M 2021 9M 2020 Change (%) Q3 2021 Q3 2020 Change (%) Revenues 4,040 2,814 43.6% 1,498 1,075 39.3% Cost of service (-) (2,969) (2,150) 38.1% (1,062) (799) 33.0% Gross profit 1,071 664 61.2% 435 277 57.4% General administration exp

  25. Slide 25: Reconciliation from Reported EBITDA to Adjusted EBITDA

    Reconciliation from Reported EBITDA to Adjusted EBITDA TLm 9M 2021 9M 2020 Q3 2021 Q3 2020 Net profit / (loss) 215 52 41 13 Tax (income) from operations 120 37 106 12 Depreciation and amortization of tangible and intangible fixed assets 238 188 84 62 Total interest expenses/(income) and fair value d

MLP Care — 9M 2021 Earnings Presentation on 6ix